Synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
=== Cocaine === Cocaine, in contrast to marijuana or alcohol, is a powerful stimulant. Upon entering the bloodstream, it rapidly reaches the brain within minutes, causing a significant surge in dopamine levels. The effects of cocaine are intense but short-lived, typically lasting about 30 minutes. The primary method of administration is through nasal insufflation (snorting), although it can also be smoked in crystal rock form. The rapid increase in dopamine levels during use contributes to a pronounced and challenging comedown, often prompting individuals to seek higher doses in subsequent use to achieve the same effects as experienced previously. This pattern can contribute to the development of addiction. The effects of cocaine use include increased energy and euphoria, accompanied by potential negative effects such as paranoia, rapid heart rate, and anxiety, among others.
For much of the early 12th century, the Wadi al-Taym and the southern Chouf were the territory of the Jandal, a Druze clan. The leader of the clan, Dahhak ibn Jandal allied with the Crusaders of the Kingdom of Jerusalem and engaged in a feud with the Assassins who ruled the Banias fortress in the western foothills of Mount Hermon just south of Wadi al-Taym. Today, the population in the area being predominantly Druze and Sunni, with a high number of Christians, mostly Greek Orthodox.
May improve mood Strengthens and enlarges the heart muscle, to improve its pumping efficiency and reduce the resting heart rate, known as aerobic conditioning May improve circulation efficiency and reduce blood pressure May help maintain independence in later life Increases the total number of red blood cells in the body, facilitating transport of oxygen Improves mental health, including reducing stress and lowering the risk of depression, as well as increased cognitive capacity. Increases the synthesis of brain-derived neurotrophic factor (BDNF), which is thought to contribute to the cognitive benefits of regular exercise. Slightly reduced depression may also be observed, especially if aerobic exercises are used as additional treatment for patients with a hematological malignancy Reduces the risk for diabetes (One meta-analysis has shown, from multiple conducted studies, that aerobic exercise does help lower Hb A1Clevels for type 2 diabetics.) Moderates the risk of death due to cardiovascular problems Promotes weight loss Reduces the risk of osteoporosis May improve episodic memory
The clipper sailing ship Dunedin, owned by the New Zealand and Australian Land Company (NZALC), was refitted in 1881 with a Bell-Coleman compression refrigeration machine. This freezer unit worked by compressing air, then releasing it into the hold of the ship. The expanding air absorbed heat as it expanded, cooling the cargo in the hold. Burning three tons of coal a day in the steam engine that ran the compressor, it could lower the temperature of the hold by 40 °F (22 °C) compared to the surrounding air temperature, which froze the cargo in the temperate climate of southern New Zealand and then maintained it below freezing (32 °F, 0 °C) through the tropics. Dunedin's most visible sign of being an unusual ship was the funnel for the refrigeration plant placed between her fore and main masts (sometimes leading her to be mistaken for a steamship which had been common since the 1840s). In February 1882, Dunedin sailed from Port Chalmers, New Zealand, with 4,331 mutton, 598 lamb and 22 pig carcasses, 246 kegs of butter, and hare, pheasant, turkey, chicken and 2,226 sheep tongues. It arrived in London after sailing 98 days with its cargo still frozen. After meeting all costs, the NZALC company made a £4,700 profit from the voyage. Soon after Dunedin's successful voyage, an extensive frozen meat trade from New Zealand and Australia to the UK was developed with over 16 different refrigerated and passenger refrigerated ships built or refitted by 1900 in Scotland and Northern England shipyards for this trade.
Sources: en.wikipedia.org
=== Diabetics === The prevention of hypoglycemia depends on the cause. In those with diabetes treated by insulin, glinides, or sulfonylurea, the prevention of hypoglycemia has a large focus on patient education and medication adjustments. The foundation of diabetes education is learning how to recognize the signs and symptoms of hypoglycemia, as well as learning how to act quickly to prevent worsening of an episode. Another cornerstone of prevention is strong self-monitoring of blood glucose, with consistent and frequent measurements. Research has shown that patients with type 1 diabetes who use continuous glucose monitoring systems with insulin pumps significantly improve blood glucose control. Insulin pumps help to prevent high glucose spikes, and help prevent inappropriate insulin dosing. Continuous glucose monitors can sound alarms when blood glucose is too low or too high, especially helping those with nocturnal hypoglycemia or hypoglycemic unawareness. In terms of medication adjustments, medication doses and timing can be adjusted to prevent hypoglycemia, or a medication can be stopped altogether.
Otherwise: Cut the potato into slices as shown above, stew with Spanish wine, oil and nutmeg. (French: Tartoufle autrement. Conppez la tartoufle par tranches comme deſſus, & la mettez eſteuuer avec vin d'Eſpagne & nouveau beure, & noix muſcade.)
=== Other endocrine conditions === Endocrine diseases that may lead to ketoacidosis include severe forms of hypothyroidism, thyrotoxicosis and adrenal failure. In all cases, the hormone-sensitive lipase in cells is phosphorylated and over-active, resulting in unrestrained lipolysis. Ketonemia and even ketoacidosis may arise from endocrine (non-diabetic) conditions alone, but the combination of endocrine and diabetic ketoacidosis leads to an especially unfavourable prognosis.
Sources: en.wikipedia.org
=== Vietnamese === Vietnamese is an isolating language, which naturally limits the length of a morpheme. The longest, at seven letters, is nghiêng, which means "inclined" or "to lean". This is the longest word that can be written without a space. However, not all words in Vietnamese are single morphemes. Indeed, nghiêng can be reduplicated as nghiêng nghiêng. The written language abounds with compound words in which each constituent word is delimited by spaces, just like any freestanding word. Moreover, the grammar lacks inflection to mark parts of speech, and prepositions are often optional. Therefore, the boundary between a word and a phrase is poorly defined. Examples of this ambiguity include:
For centuries, the Danes and Saxons had regarded each other as kindred peoples, sharing the same belief in the Germanic pantheon and frequently intermarrying, especially among the elite. Thus, the defeated Saxon warleader Widukind sought refuge with his father-in-law, Danish king Sigfred. The Royal Frankish Annals mentions that Widukind received substantial aid from Sigfred, though the exact nature of this aid is not explicitly stated. However, the chronicles do note that Sigfred and Charlemagne brokered a peace agreement some years later, indicating that Sigfred, upon hearing Widukind's plea, may have mustered his army and joined the war on the side of the Saxons. In response to the Danes' involvement in the war, Charlemagne seems to have recruited the Obotrites by promising them the Saxon portion of Holstein. This alliance with Charlemagne shifted the balance of power in the region. In 782, after another defeat of the Saxons, Charlemagne ordered the mass execution of 4,500 Saxons, an atrocity that became known as the Massacre of Verden. Following this brutal act, Charlemagne was nicknamed the "Butcher of Saxons" or "Saxonslaughterer." In 796, despite Saxony being fully under Frankish rule, the Saxons rose once more, supported by the Danes. The rebellion was triggered by the forced conscription of Saxons for the Frankish wars against the Avars. Moreover, Charlemagne, in alliance with the Obotrites, planned to subjugate the Danes, now led by King Gudfred Sigfredson. However, Gudfred struck first.
To motivate intermediaries the firm can use positive actions, such as offering higher margins to the intermediary, special deals, premiums and allowances for advertising or display. On the other hand, negative actions may be necessary, such as threatening to cut back on margin, or hold back delivery of product. Care must be exercised when considering negative actions as these may fall foul of regulations and can contribute to a public backlash and a public relations disaster. Manufacturer complacency has been highlighted as a risk leading distributors to move their business to other supply lines.
== Therapeutics == Several mimetics of ELA have been developed for therapeutic purposes. Amgen has created a camel antibody and a small molecule agonist capable of mimicking the function of ELA towards it cognate receptor APLNR. The latter has entered phase 1 clinical trials for heart failure and acute kidney disease. Bristol Myers Squibb has also created its own small molecule agonist of APLNR. An opinion published in the Lancet in 2019 suggested that ELABELA could be used to treat intrauterine growth restriction and maternal morbidity linked to eclampsia.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.